Hot Features
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expre... Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.07 | 0.866336633663 | 8.08 | 8.44 | 7.86 | 67417 | 8.11827607 | CS |
| 4 | -0.49 | -5.6712962963 | 8.64 | 9.4734 | 7.02 | 87999 | 8.11683537 | CS |
| 12 | 1.2 | 17.2661870504 | 6.95 | 9.4734 | 6.05 | 115770 | 7.79484665 | CS |
| 26 | 7.679 | 1630.36093418 | 0.471 | 9.4734 | 0.47 | 183276 | 5.88108444 | CS |
| 52 | 7.4863 | 1127.96444177 | 0.6637 | 9.4734 | 0.4601 | 851704 | 1.25767204 | CS |
| 156 | 3.49 | 74.8927038627 | 4.66 | 9.4734 | 0.4471 | 858788 | 1.59340524 | CS |
| 260 | -1.55 | -15.9793814433 | 9.7 | 21.87 | 0.4471 | 735038 | 4.88000806 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.